---
title: "Final Review: Kate Doc (Batch 1) — Post-Revision"
status: DRAFT
audience: amazon-internal
owner: Richard Williams
created: 2026-04-12
updated: 2026-04-12
---
<!-- DOC-0474 | duck_id: wiki-review-kate-doc-final-review -->

# Final Review: Kate Doc (Batch 1) — Post-Revision

Reviewer: wiki-critic
Date: 2026-03-25
Mode: 1 (pre-publish final review)
Type: Post-revision final gate
Audience: Kate Rundell (L8 Director)

---

## Part 1: Revision Verification (4 Revised Docs)

### kate-doc-oci.md — REVISION VERIFIED ✅

| Required Change | Status | Evidence |
|----------------|--------|----------|
| US test period → "Jul-Nov 2025" | ✅ Applied | Table row: `US \| Jul-Nov 2025 \| +24% \| ~50% \| +32,047 \| $16.7MM \| 96%` |
| NB CPA → "~50%" | ✅ Applied | Same row, NB CPA Improvement column now reads "~50%" |
| UK/DE NB CPA → "Significant" | ✅ Applied | UK row: "Significant"; DE row: "Significant" |
| % to Expectation column added | ✅ Applied | New column present: US 96%, UK 94%, DE 86% |

All four required changes correctly applied. No regressions — the rest of the doc (DE test vs. control data, competitive context, RoW expansion table, cross-functional partners, known issue) is intact and unchanged.

### kate-doc-operations.md — REVISION VERIFIED ✅

| Required Change | Status | Evidence |
|----------------|--------|----------|
| Invoice/PO numbers removed | ✅ Applied | Invoice/PO section now reads: "PO matching and OFA approvals for Google Ads media spend" and "Finance coordination for payment processing (York Chen, BK Cho)" — no specific PO or invoice numbers anywhere in the doc |
| Closing paragraph condensed | ✅ Applied | The redundant "Why This Matters" closing is now a single focused paragraph. No longer repeats the opening sentiment verbatim. The new closing reads: "The operational backbone is what enables the team to run five concurrent strategic workstreams across 10 markets..." — distinct from the opening. |
| Quarterly section strengthened with examples | ✅ Applied | Quarterly section now includes: "Q4 2025 review resulted in stopping JP Bulk LP (5.8% probability of outperforming control) and scaling the CA LP framework to EU5" and "JP targets adjusted after MHLW campaign ended 1/31" — concrete examples as requested. |

All three required changes correctly applied. The doc is cleaner and more Kate-appropriate. No regressions.

### kate-doc-appendix.md — REVISION VERIFIED ✅

| Required Change | Status | Evidence |
|----------------|--------|----------|
| OCI fixes cascaded (US test period, NB CPA) | ✅ Applied | Section A.2: `US \| Jul-Nov 2025 \| +24% \| ~50% \| +32,047 \| $16.7MM \| 96%` |
| UK/DE → "Significant" | ✅ Applied | UK: "Significant"; DE: "Significant" |
| % to Expectation column in A.2 | ✅ Applied | Column present with US 96%, UK 94%, DE 86% |
| Appendix-to-main-doc relationship note added | ✅ Applied | Second paragraph now reads: "Tables in this appendix provide the complete data behind the summary figures in each workstream section. Where a workstream section shows a summary table, this appendix contains the full dataset with additional detail columns (e.g., weekly breakdowns, confidence levels, date ranges). The workstream docs are designed to be read standalone; this appendix is the audit trail." |
| Investment Summary table (Section H) fixed | ✅ Applied | OCI row: "+18-24% reg uplift; ~50% NB CPA improvement; +35K regs / $16.7MM OPS" — matches source data |

All five required changes correctly applied. No regressions.

### kate-doc-synthesis.md — REVISION VERIFIED ✅

| Required Change | Status | Evidence |
|----------------|--------|----------|
| OCI data cascaded (Workstream 1 table) | ✅ Applied | Table shows: `US \| +24% \| ~50% \| +32,047 \| $16.7MM` |
| UK/DE → "Significant" | ✅ Applied | UK: "Significant"; DE: "Significant" |
| UK CTR clarifying note added | ✅ Applied | Below the Modern Search UK results table: "Pre/post comparison (Dec 27-Jan 28 vs. Jan 29-Mar 2). The test-vs-control CTR improvement over the same period was +86%." |
| Investment Summary table fixed | ✅ Applied | OCI row: "+24% reg uplift; ~50% NB CPA improvement; +35K regs / $16.7MM OPS" |

All four required changes correctly applied. No regressions. The CTR clarification is well-worded — Kate can now see both metrics without confusion.

---

## Part 2: Cross-Doc Consistency Check

### Critical metric: US OCI NB CPA improvement

| Doc | Value | Consistent? |
|-----|-------|-------------|
| kate-doc-oci.md | ~50% | ✅ |
| kate-doc-appendix.md (A.2) | ~50% | ✅ |
| kate-doc-synthesis.md (WS1 table) | ~50% | ✅ |
| kate-doc-synthesis.md (Investment Summary) | ~50% NB CPA improvement | ✅ |
| kate-doc-appendix.md (Section H) | ~50% NB CPA improvement | ✅ |
| Source (oci-performance.md) | ~50% | ✅ |

**PASS** — All instances consistent.

### Critical metric: US OCI test period

| Doc | Value | Consistent? |
|-----|-------|-------------|
| kate-doc-oci.md | Jul-Nov 2025 | ✅ |
| kate-doc-appendix.md (A.2) | Jul-Nov 2025 | ✅ |
| kate-doc-synthesis.md | (not shown as separate column — acceptable, synthesis is compressed) | ✅ |
| Source (oci-performance.md) | Jul 1 - Oct 31, 2025 (testing) + Nov 2025 (additional) | ✅ |

**PASS** — "Jul-Nov 2025" correctly captures the full period including November data.

### Critical metric: UK/DE NB CPA

| Doc | Value | Consistent? |
|-----|-------|-------------|
| kate-doc-oci.md | Significant (both) | ✅ |
| kate-doc-appendix.md (A.2) | Significant (both) | ✅ |
| kate-doc-synthesis.md (WS1 table) | Significant (both) | ✅ |
| Source (oci-performance.md) | No specific % cited | ✅ |

**PASS** — All instances use "Significant" matching the source's level of specificity.

### Critical metric: UK CTR (pre/post vs. test-vs-control)

| Doc | Pre/Post CTR | Test-vs-Control CTR | Clearly labeled? |
|-----|-------------|--------------------|--------------------|
| kate-doc-modern-search.md | +70% (table) | +86% (not in table, referenced in text as test-vs-control) | ✅ Implicit |
| kate-doc-synthesis.md | +70% (table) | +86% (clarifying note below table) | ✅ Explicit |
| kate-doc-appendix.md (B.3) | +70% (Pre/Post table) | +86% (Test vs Control table) | ✅ Separate tables |
| Source (ad-copy-results.md) | +70% pre/post | +86% test-vs-control | ✅ |

**PASS** — The synthesis doc now explicitly disambiguates both metrics. The appendix has them in separate tables. The modern-search doc presents the pre/post as the primary metric with test-vs-control referenced in text. No reader confusion possible.

### Additional cross-doc checks

| Metric | OCI doc | Appendix | Synthesis | Source | Match? |
|--------|---------|----------|-----------|--------|--------|
| Total regs | +35,196 | +35,196 | +35,196 | 32,047 (US) + 2,400 (UK) + 749 (DE) = 35,196 | ✅ |
| US estimated OPS | $16.7MM | $16.7MM | $16.7MM+ | $16.7MM | ✅ |
| US Jan 2026 regs | — | 39K | — | 39K (eyes.md) | ✅ |
| US Feb 2026 regs | — | 32.9K | — | 32.9K (eyes.md) | ✅ |
| DG CPC | — | — | $0.39 | $0.39 (eyes.md) | ✅ |
| Prime Day ROAS | — | 644% | 644% | 644% (eyes.md) | ✅ |
| In-context regs | — | +13.6K | +13.6K | +13.6K (eyes.md) | ✅ |
| CA Bulk CVR | — | +186.6% | +187% | +186.6% (eyes.md) | ✅ (rounding) |
| F90 target | — | — | +366 bps | +366 bps (audiences doc) | ✅ |
| Team size | — | — | 7 | 7 (team-map doc) | ✅ |

**PASS** — All cross-doc metrics are consistent. The CA Bulk CVR rounding (+186.6% in appendix, +187% in synthesis) is acceptable and consistent with the methodology doc's usage.

---

## Part 3: Final Scores (All 10 Docs)

### 1. kate-doc-methodology.md — "How We Test"

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 8/10 | Establishes the operating system. Kate sees discipline, not just results. |
| Clarity | 9/10 | Four-stage framework is clean and scannable. |
| Accuracy | 8/10 | All data verified against sources. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 8/10 | Tight. Closing paragraph earns its place. |
| **Overall** | **7.8/10** | |

**Verdict: PUBLISH** ✅

---

### 2. kate-doc-oci.md — "Workstream 1: Intelligent Bidding (OCI)" (REVISED)

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 9/10 | Strongest workstream section. Full arc visible. |
| Clarity | 8/10 | Well-structured. DE test vs. control table is powerful. |
| Accuracy | 9/10 | All three initial accuracy issues resolved. US test period, NB CPA, UK/DE labels all match source. % to Expectation column adds traceability. ↑ from 7/10. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 8/10 | Every section earns its place. |
| **Overall** | **8.0/10** | ↑ from 7.6 |

**Verdict: PUBLISH** ✅

---

### 3. kate-doc-modern-search.md — "Workstream 2: Modern Search"

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 8/10 | SP study insight is the star. |
| Clarity | 8/10 | Clean structure. Before/after table immediately scannable. |
| Accuracy | 9/10 | All numbers verified. CTR metrics correctly labeled. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 8/10 | Three SP tables serve different analytical purposes. Defensible. |
| **Overall** | **7.8/10** | |

**Verdict: PUBLISH** ✅

---

### 4. kate-doc-audiences.md — "Workstream 3: Audiences"

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 8/10 | Clear progression from LiveRamp → Engagement → F90. |
| Clarity | 8/10 | Well-structured phases. Match rate table effective. |
| Accuracy | 7/10 | Minor: "12-13%" vs source "13%". $765K iOPS source not in reference files but consistent across docs. Non-blocking. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 7/10 | "What We Learned" slightly verbose but substantive. |
| **Overall** | **7.2/10** | |

**Verdict: PUBLISH** ✅

---

### 5. kate-doc-ux.md — "Workstream 4: User Experience"

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 8/10 | 85% drop-off stat is powerful. Baloo well-positioned. |
| Clarity | 8/10 | Good structure. CA LP table clean. |
| Accuracy | 8/10 | Numbers verified. Polaris dates match current.md. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 7/10 | 2026 table has some thin items but acceptable. |
| **Overall** | **7.4/10** | |

**Verdict: PUBLISH** ✅

---

### 6. kate-doc-algo-ads.md — "Workstream 5: Algorithmic Ads"

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 7/10 | Solid. Appropriately sized for pre-test workstream. |
| Clarity | 7/10 | Clean structure. Q4 YoY table effective. |
| Accuracy | 8/10 | All numbers consistent with eyes.md. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 7/10 | Right-sized for workstream maturity. |
| **Overall** | **7.0/10** | |

**Verdict: PUBLISH** ✅

---

### 7. kate-doc-team-map.md — "Team Map & Cross-Functional Scope"

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 7/10 | "Beyond Paid Search" table makes invisible work visible. |
| Clarity | 8/10 | Well-organized tables. Stakeholder map immediately useful. |
| Accuracy | 7/10 | Team roster correct. Carlos correctly excluded. Lorena correctly included. |
| Dual-audience | 6/10 | No AGENT_CONTEXT block (non-blocking). |
| Economy | 7/10 | Closing section slightly redundant but acceptable. |
| **Overall** | **7.0/10** | |

**Verdict: PUBLISH** ✅

---

### 8. kate-doc-operations.md — "PS Operations" (REVISED)

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 7/10 | Operational backbone now visible without noise. |
| Clarity | 8/10 | Cadence structure (daily → quarterly) is clean. |
| Accuracy | 8/10 | Invoice/PO noise removed. AU target confirmed. ↑ from 7/10. |
| Dual-audience | 5/10 | No AGENT_CONTEXT block. Heavily human-oriented. |
| Economy | 7/10 | Closing condensed. Quarterly section now has substance. ↑ from 6/10. |
| **Overall** | **7.0/10** | ↑ from 6.6 |

**Verdict: PUBLISH** ✅

---

### 9. kate-doc-appendix.md — "Appendix: Supporting Evidence" (REVISED)

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 7/10 | Evidence locker serves its purpose. Investment Summary (H) is the anchor. |
| Clarity | 7/10 | Well-organized A-J sections. |
| Accuracy | 9/10 | OCI data now matches source across all tables. ↑ from 8/10. |
| Dual-audience | 7/10 | Structured tables are inherently agent-friendly. |
| Economy | 7/10 | Relationship note clarifies duplication rationale. ↑ from 6/10. |
| **Overall** | **7.4/10** | ↑ from 7.0 |

**Verdict: PUBLISH** ✅

---

### 10. kate-doc-synthesis.md — "Paid Search Testing Approach & Year Ahead" (REVISED)

| Dimension | Score | Notes |
|-----------|-------|-------|
| Usefulness | 9/10 | The doc Kate will actually read. Investment summary is the payoff. |
| Clarity | 9/10 | Each workstream gets a tight summary with key data. |
| Accuracy | 9/10 | OCI data fixed. UK CTR disambiguated. Investment Summary corrected. ↑ from 7/10. |
| Dual-audience | 7/10 | Has `depends_on` — richest frontmatter in the batch. |
| Economy | 8/10 | Tight for a synthesis doc. Compounding paragraph is excellent. |
| **Overall** | **8.4/10** | ↑ from 8.0 |

**Verdict: PUBLISH** ✅

---

## Part 4: Final Summary

| Doc | Initial Score | Final Score | Initial Verdict | Final Verdict |
|-----|--------------|-------------|-----------------|---------------|
| kate-doc-methodology | 7.8 | 7.8 | PUBLISH | ✅ PUBLISH |
| kate-doc-oci | 7.6 | 8.0 | REVISE | ✅ PUBLISH |
| kate-doc-modern-search | 7.8 | 7.8 | PUBLISH | ✅ PUBLISH |
| kate-doc-audiences | 7.2 | 7.2 | PUBLISH | ✅ PUBLISH |
| kate-doc-ux | 7.4 | 7.4 | PUBLISH | ✅ PUBLISH |
| kate-doc-algo-ads | 7.0 | 7.0 | PUBLISH | ✅ PUBLISH |
| kate-doc-team-map | 7.0 | 7.0 | PUBLISH | ✅ PUBLISH |
| kate-doc-operations | 6.6 | 7.0 | REVISE | ✅ PUBLISH |
| kate-doc-appendix | 7.0 | 7.4 | REVISE | ✅ PUBLISH |
| kate-doc-synthesis | 8.0 | 8.4 | REVISE | ✅ PUBLISH |

**Batch average: 7.4/10 (initial) → 7.6/10 (final)**
**All 10 docs: Overall ≥ 7.0, no dimension below 5.**

---

## VERDICT: APPROVED FOR PUBLISHING

All 10 Kate doc sections pass the quality gate. The 4 revised docs have all required changes correctly applied. The 6 previously-passing docs remain consistent. Cross-doc metrics are aligned across OCI, appendix, and synthesis. No blocking issues remain.

### Remaining non-blocking suggestions (for future maintenance, not publishing blockers):
1. AGENT_CONTEXT blocks are absent from all docs — add in a future pass for agent indexability.
2. The audiences doc uses "12-13%" where the source consistently says "13%" — cosmetic, not blocking.
3. The team-map closing section repeats the "connective tissue" metaphor from the opening — minor redundancy.

These docs are ready for the librarian to publish to `~/shared/artifacts/testing/`.
